搜尋結果
COVID-19 vaccine. How COVID‑19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect. Part of a series on the. COVID-19 pandemic. Scientifically accurate atomic model of the external structure of SARS-CoV-2.
- none
- Intramuscular
- mRNA, viral, inactivated, protein
- SARS-CoV-2
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm. [1] [2]
- .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}, Full list of Sinopharm NVSI authorizations
- SARS-CoV-2
The COVID-19 pandemic arrived in Europe with its first confirmed case in Bordeaux, France, on 24 January 2020, and subsequently spread widely across the continent. By 17 March 2020, every country in Europe had confirmed a case,[312]and all had reported at least one death, with the exception of Vatican City.
- 6,956,160 (reported), 17.5–31.4 million (estimated)
- Worldwide
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndromecoronavirus 2 (SARS‑CoV‑2)
- 新冠肺炎-疫苗資訊最前線
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [1] [2] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [3] .
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2.The first known case was identified in Wuhan, China, in December 2019. The disease quickly spread worldwide, resulting in the ongoing COVID-19 pandemic.The symptoms of COVID‑19 are variable but often include fever, fatigue, cough, breathing difficulties, loss of smell, and loss of taste.
- 6,960,770 (reported), 17.6–31.4 million (estimated)
- SARS-CoV-2
- 2–14 days (typically 5), after infection
- Symptomatic and supportive
Indian Council of Medical Research National Institute of Virology [1] On 3 November 2021, the (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved. [2] [3] By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries. [4]
Sinovac Biotech Ltd. ( Chinese: 科兴控股生物技术有限公司) is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases.